Gerard Norton was featured in the Law360 article, "Alexion To Buy Synageva For $8.4B In Latest Big Pharma Deal." Full text can be found in the May 6, 2015, issue, but a synopsis is noted below.
Alexion Pharmaceuticals, Inc., recently completed a deal to buy fellow pharma company Syngeva BioPharma Corp. for $8.4 billion. This acquisition follows the recent trend of consolidation in the pharma industry over the last year.
Alexion bought Syngeva in order to advance their drug development in the areas of devastating and rare diseases.
Gerard Norton led a team of Fox Rothschild attorneys to handle the intellectual property due diligence portion of the deal for Alexion.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
